Compare
Bioxytran, Inc vs Provectus Biopharmaceuticals, Inc. vs ProtoKinetix, Inc. vs Ocean Biomedical, Inc.
| Latest fiscal year | Bioxytran, Inc BIXT | Provectus Biopharmaceuticals, Inc. PVCT | ProtoKinetix, Inc. PKTX | Ocean Biomedical, Inc. OCEALast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2024-12-31 |
| Revenue | n/a | $336.1K | n/a | n/a |
| Revenue growth (YoY) | n/a | -45.5% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$2.12M | -$5.43M | -$393.6K | -$9.48M |
| EPS (Diluted) | -$0.02 | -$0.01 | $0.00 | -$0.34 |
| Operating cash flow | -$526.5K | -$3.33M | -$135.4K | -$4.18M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | $251.3K | n/a | n/a |
| Total assets | $658.6K | $697.5K | $483.4K | $902.0K |
| Total liabilities | $3.25M | $7.00M | n/a | $98.52M |
| Shareholders' equity | -$2.59M | -$6.30M | $297.9K | -$97.62M |
| Return on year-end equity | n/a | n/a | -132.1% | n/a |
| Shares outstanding | 108.15M | 420.28M | 406.83M | 34.87M |
Revenue, most recent five fiscal years
| Fiscal year | Bioxytran, Inc | Provectus Biopharmaceuticals, Inc. | ProtoKinetix, Inc. | Ocean Biomedical, Inc. |
|---|---|---|---|---|
| Latest | $191.1K Ended 2017-12-31 | $336.1K Ended 2025-12-31 | $0 Ended 2014-12-31 | n/a |
| 1 year earlier | $246.5K Ended 2016-12-31 | $617.1K Ended 2024-12-31 | $0 Ended 2013-12-31 | n/a |
| 2 years earlier | $255.8K Ended 2015-12-31 | $557.7K Ended 2023-12-31 | $0 Ended 2012-12-31 | n/a |
| 3 years earlier | $275.6K Ended 2014-12-31 | $989.0K Ended 2022-12-31 | $0 Ended 2011-12-31 | n/a |
| 4 years earlier | $417.3K Ended 2013-12-31 | n/a | $0 Ended 2010-12-31 | n/a |